Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

5 results
10:20 AM, Apr 12, 2018  |  BC Extra | Financial News

Abpro planning $69M NASDAQ listing

to develop it to treat HER2-positive solid tumors in Orphan indications. ABP-201 targets VEGF and angiopoietin 2
ANG2; ANPT2). The company intends to develop that antibody to treat vascular diseases of the eye …
2:10 PM, Nov 27, 2017  |  BC Extra | Clinical News

Regeneron discontinues Eylea/nesvacumab combo

data from the trials before deciding on how to proceed with nesvacumab, a mAb against angiopoietin 2
ANG2; ANGPT2). He said Regeneron has not disclosed whether the candidate is in testing for other …
5:45 PM, Mar 24, 2016  |  BC Extra | Company News

Regeneron, Bayer strike another Eylea combo deal

wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Nesvacumab is a mAb against angiopoietin 2
ANG2 ; ANGPT2 ). Eylea is a human fusion protein that binds all forms of …
commercialization rights and will retain all profits from U.S. sales. According to the companies, targeting ANG2
4:53 PM, May 03, 2013  |  BC Extra | Top Story

Regeneron gains after 1Q13 results

targeting platelet derived growth factor (PDGF) for all indications including ophthalmology, and to antibodies targeting angiopoietin 2
ANG2 ; ANGPT2 ) for ophthalmology indications only. Sanofi will receive $10 million up front …
40 million in milestones for the PDGF antibodies and a $5 million milestone for the ANG2
5:33 PM, Dec 18, 2007  |  BC Extra | Company News

Pfizer to acquire CovX

CVX-045, a thrombospondin-1 ( TSP-1 ) mimetic in Phase I testing for cancer; CVX-060, an angiopoietin 2
Ang2) antagonist for which Phase I testing to treat cancer is expected to begin this month …